Skip to main content
. 2013 Oct 22;6:79. doi: 10.1186/1756-8722-6-79

Figure 1.

Figure 1

Rates of grade ≥3 thrombocytopenia and anemia in COMFORT-I. (From Verstovsek, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis [16]. © 2012 Massachusetts Medical Society. Reprinted with permission from the Massachusetts Medical Society). Shown are mean percentages of (A) grade ≥3 thrombocytopenia and (B) grade ≥3 anemia per month over time.